Does a rise in the BCR‐ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
D Marin, JS Khorashad, L Foroni… - British journal of …, 2009 - Wiley Online Library
BCR‐ABL1 transcript numbers were monitored in 161 patients who started treatment with
imatinib early after diagnosis of chronic myeloid leukaemia in chronic phase and achieved …
imatinib early after diagnosis of chronic myeloid leukaemia in chronic phase and achieved …
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome—positive chronic myeloid leukemia after failure of interferon-α
J Cortes, F Giles, S O'Brien, D Thomas… - Blood, 2003 - ashpublications.org
Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after
interferon failure, although only a few patients achieve a molecular remission. We …
interferon failure, although only a few patients achieve a molecular remission. We …
Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response
F Cervantes, JG Correa, I Pérez, V García-Gutiérrez… - Annals of …, 2017 - Springer
To determine whether a lower imatinib dose could minimize toxicity while maintaining the
molecular response (MR), imatinib dose was reduced to 300 mg daily in 43 patients with …
molecular response (MR), imatinib dose was reduced to 300 mg daily in 43 patients with …
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
Mutations within the BCR-ABL kinase domain in imatinib-treated chronic myeloid leukemia
(CML) are the main mechanism of acquired resistance. The early detection of mutations …
(CML) are the main mechanism of acquired resistance. The early detection of mutations …
Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing
E Faber, J Naušová, M Jarošová, MJ Egorin… - Leukemia & …, 2006 - Taylor & Francis
Hematologic toxicity is reported as one of the most important problems connected with
imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML) …
imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML) …
Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients
CB Gambacorti-Passerini, F Rossi, M Verga… - Blood Cells, Molecules …, 2002 - Elsevier
Imatinib mesylate (imatinib) inhibits Bcr/Abl, an oncogenic fusion protein. The in vitro effects
of imatinib on BCR/ABL+ leukemic cells include inhibition of Bcr/Abl tyrosine …
of imatinib on BCR/ABL+ leukemic cells include inhibition of Bcr/Abl tyrosine …
Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic‐phase chronic myeloid leukemia
N Takahashi, H Wakita, M Miura… - Clinical …, 2010 - Wiley Online Library
Despite the outstanding results generally obtained with imatinib mesylate (IM) in the
treatment of chronic myeloid leukemia (CML), some patients show a poor molecular …
treatment of chronic myeloid leukemia (CML), some patients show a poor molecular …
Personalized daily doses of imatinib by therapeutic drug monitoring increase the rates of molecular responses in patients with chronic myeloid leukemia. Final results …
P Rousselot, H Johnson-Ansah, F Huguet, L Legros… - 2015 - ashpublications.org
Background Imatinib mesylate (IM) at 400 mg/d remains a standard for first line therapy in
patients (pts) with newly diagnosed chronic phase CML (CP-CML). A sub analysis of the …
patients (pts) with newly diagnosed chronic phase CML (CP-CML). A sub analysis of the …
Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients
S Hayette, M Michallet, ML Baille, JP Magaud… - Leukemia research, 2005 - Elsevier
Quantitative monitoring of imatinib mesylate (IM)-resistant, mutated BCR-ABL+ cells during
the follow-up of CML could be useful for optimizing therapeutic management. We …
the follow-up of CML could be useful for optimizing therapeutic management. We …
[HTML][HTML] Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy.
F Guilhot, RA Larson, SG O'Brien, I Gathmann… - Blood, 2007 - Elsevier
Abstract Background: Results from the International Randomized Study of Interferon and
STI571 (IRIS) trial showed that achievement of a CCyR is prognostically relevant for long …
STI571 (IRIS) trial showed that achievement of a CCyR is prognostically relevant for long …